CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCE ANALYSIS
3.4. GOVERNMENT REGULATIONS
3.5. TOP PLAYER POSITIONING
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in healthcare expenditure
3.6.1.2. Increase in R&D investments
3.6.1.3. Growth in proteomics research
3.6.1.4. Rise in incidence of chronic diseases

3.6.2. Restraints

3.6.2.1. High production costs

3.6.3. Opportunities

3.6.3.1. Training for professionals
3.6.3.2. Greater potency with reduced costs and increasing affordability
3.6.3.3. Untapped emerging markets

CHAPTER 4 PROTEIN THERAPEUTICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MONOCLONAL ANTIBODY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. FUSION PROTEIN

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. ERYTHROPOIETIN

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. INTERFERON

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. HUMAN GROWTH HORMONE

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast

4.8. FOLLICLE-STIMULATING HORMONE

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 PROTEIN THERAPEUTICS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. METABOLIC DISORDERS

5.2.1. Market size and forecast

5.3. IMMUNOLOGICAL DISORDERS

5.3.1. Market size and forecast

5.4. HEMATOLOGICAL DISORDERS

5.4.1. Market size and forecast

5.5. CANCER

5.5.1. Market size and forecast

5.6. HORMONAL DISORDERS

5.6.1. Market size and forecast

5.7. GENETIC DISORDERS

5.7.1. Market size and forecast

5.8. OTHERS

5.8.1. Market size and forecast

CHAPTER 6 PROTEIN THERAPEUTICS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast, by country

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast, by country
6.2.4. Market size and forecast, by product
6.2.5. Market size and forecast, by application

6.2.5.1. U.S. market size and forecast, by product
6.2.5.2. U.S. market size and forecast, by application
6.2.5.3. Canada market size and forecast, by product
6.2.5.4. Canada market size and forecast, by application
6.2.5.5. Mexico market size and forecast, by product
6.2.5.6. Mexico market size and forecast, by application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast, by country
6.3.4. Market size and forecast, by product
6.3.5. Market size and forecast, by application

6.3.5.1. Germany market size and forecast, by product
6.3.5.2. Germany market size and forecast, by application
6.3.5.3. France market size and forecast, by product
6.3.5.4. France market size and forecast, by application
6.3.5.5. UK market size and forecast, by product
6.3.5.6. UK market size and forecast, by application
6.3.5.7. Italy market size and forecast, by product
6.3.5.8. Italy market size and forecast, by application
6.3.5.9. Spain market size and forecast, by product
6.3.5.10. Spain market size and forecast, by application
6.3.5.11. Rest of Europe market size and forecast, by product
6.3.5.12. Rest of Europe market size and forecast, by application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast, by country
6.4.4. Market size and forecast, by product
6.4.5. Market size and forecast, by application

6.4.5.1. Japan market size and forecast, by product
6.4.5.2. Japan market size and forecast, by application
6.4.5.3. China market size and forecast, by product
6.4.5.4. China market size and forecast, by application
6.4.5.5. Australia market size and forecast, by product
6.4.5.6. Australia market size and forecast, by application
6.4.5.7. India market size and forecast, by product
6.4.5.8. India market size and forecast, by application
6.4.5.9. South Korea market size and forecast, by product
6.4.5.10. South Korea market size and forecast, by application
6.4.5.11. Taiwan market size and forecast, by product
6.4.5.12. Taiwan market size and forecast, by application
6.4.5.13. Rest of Asia-Pacific market size and forecast, by product
6.4.5.14. Rest of Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast, by country
6.5.4. Market size and forecast, by product
6.5.5. Market size and forecast, by application

6.5.5.1. Brazil market size and forecast, by product
6.5.5.2. Brazil market size and forecast, by application
6.5.5.3. Saudi Arabia market size and forecast, by product
6.5.5.4. Saudi Arabia market size and forecast, by application
6.5.5.5. South Africa market size and forecast, by product
6.5.5.6. South Africa market size and forecast, by application
6.5.5.7. Rest of LAMEA market size and forecast, by product
6.5.5.8. Rest of LAMEA market size and forecast, by application

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AMGEN, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. HOFFMANN-LA ROCHE AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. JOHNSON & JOHNSON

7.6.1. Company overview
7.6.2. Company Snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. MERCK & CO., INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVO NORDISK A/S

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. PFIZER INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. SANOFI

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments